Lung Cancer News and Research

Latest Lung Cancer News and Research

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Gene mutations increase as people age, which helps explain why cancer usually strikes older people. But what other consequences of aging promote cancer development or protect against it?

22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Blood-Based Protein Test May Distinguish Between Malignant And Benign Lung Nodules

...

17 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Detroit Lions, Josephine Ford Cancer Institute to raise $15M for cancer research in metro Detroit

The Detroit Lions and Josephine Ford Cancer Institute, Michigan's largest provider of adult cancer care, have created a unique partnership with the goal to raise $15 million during the next three years for cancer research in metro Detroit.

16 Oct 2013

Trovagene launches pharmaceutical alliance to monitor lung cancer patients' EGFR mutational status

Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.

16 Oct 2013

Simple blood test can help diagnose early-stage lung and prostate cancers

Early-stage lung and prostate cancers as well as their recurrence can be detected with a simple blood test, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting.

16 Oct 2013

Sexual dysfunction ‘ignored in COPD’

Researchers say that physicians should address sexual issues in patients with chronic obstructive pulmonary disease as a matter of course, after finding that over three-quarters of men with the condition have some level of erectile dysfunction.

15 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

Study evaluates economic cost of cancer across 27 countries of the EU

The first ever study to evaluate the economic cost of cancer across the 27 countries of the EU has found that the total cost of cancer in the EU in 2009 was €126 billion, with cancer in Germany, France, Italy, and the UK together accounting for just over two-thirds of this cost (€83 billion).

15 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

Lung Cancer News and Research

Latest Lung Cancer News and Research

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Clinical trials will help to develop treatment and follow-up of COPD patients

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Study opens doors to novel treatments for aggressive brain cancer

Einstein researchers receive $2.8M grant to focus on vexing question related to aging and cancer risk

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

New investigational drug offers potential treatment option for lung cancer

Recombinant hormone could REPLACE calcium supplements

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

Blood-Based Protein Test May Distinguish Between Malignant And Benign Lung Nodules

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Detroit Lions, Josephine Ford Cancer Institute to raise $15M for cancer research in metro Detroit

Trovagene launches pharmaceutical alliance to monitor lung cancer patients' EGFR mutational status

Simple blood test can help diagnose early-stage lung and prostate cancers

Sexual dysfunction ‘ignored in COPD’

Promising new type of cancer treatment to benefit more patients

Study evaluates economic cost of cancer across 27 countries of the EU

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in